1-20 of 31022
Sort by
Journal Article
ACCEPTED MANUSCRIPT
Athanasios Fountas and others
European Journal of Endocrinology, lvaf091, https://doi.org/10.1093/ejendo/lvaf091
Published: 30 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Elif Kelestemur and others
European Journal of Endocrinology, lvaf089, https://doi.org/10.1093/ejendo/lvaf089
Published: 29 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Dipika R Mohan and others
European Journal of Endocrinology, lvaf086, https://doi.org/10.1093/ejendo/lvaf086
Published: 29 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Nasri Fatih and others
European Journal of Endocrinology, lvaf090, https://doi.org/10.1093/ejendo/lvaf090
Published: 29 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Onnicha Suntornlohanakul and others
European Journal of Endocrinology, lvaf088, https://doi.org/10.1093/ejendo/lvaf088
Published: 29 April 2025
Journal Article
ACCEPTED MANUSCRIPT
Juan J Martin-Olmedo and others
European Journal of Endocrinology, lvaf087, https://doi.org/10.1093/ejendo/lvaf087
Published: 29 April 2025
Image
Published: 29 April 2025
Graphical Abstract Graphical Abstract
Journal Article
Antoan Stefan Sojat and others
European Journal of Endocrinology, Volume 192, Issue 4, April 2025, Pages 491–509, https://doi.org/10.1093/ejendo/lvaf005
Published: 28 April 2025
Image
Published: 28 April 2025
Figure 1. Geographic representation of participating centers in Europe. ITC, inclusiveness target country; non-ITC, non-inclusiveness target country.
Image
Published: 28 April 2025
Figure 4. Proportion of retrospective studies with dedicated funding for information technologies, ethical, and regulatory requirements. Total number of answers: N = 19 for ITC and N = 40 non-ITC participants. (A) Proportion of retrospective studies with dedicated funding for IT. (B) Proportion of retrosp
Image
Published: 28 April 2025
Figure 2. Cumulative proportion of adrenal centers using EHRs for clinical data collection. ITC, inclusiveness target country; non-ITC, non-inclusiveness target country; EHRs, electronic health records.
Image
Published: 28 April 2025
Figure 3. Proportion of clinical studies with dedicated funding. Total number of answers: N = 19 for ITC and N = 40 non-ITC participants. (A) Proportion of clinical trials with dedicated funding. (B) Proportion of registry-based and cohort studies with dedicated funding. (C) Proportion of retrospective st
Journal Article
ACCEPTED MANUSCRIPT
Skand Shekhar and others
European Journal of Endocrinology, lvaf083, https://doi.org/10.1093/ejendo/lvaf083
Published: 23 April 2025
Journal Article
Judith A P Bons and others
European Journal of Endocrinology, Volume 192, Issue 4, April 2025, Pages L19–L20, https://doi.org/10.1093/ejendo/lvaf075
Published: 21 April 2025
Journal Article
Qingbo Li and others
European Journal of Endocrinology, Volume 192, Issue 4, April 2025, Pages L17–L18, https://doi.org/10.1093/ejendo/lvaf040
Published: 18 April 2025
Image
Published: 16 April 2025
Figure 1. Flowchart of the study. Women with and without PCOS were identified at age 31 and the same participants were reassessed at age 46, with no additional PCOS evaluations conducted at the later age. COC, combined oral contraceptive; FAI, free androgen index; HGS, handgrip strength; HRT, hormone replacem
Image
Published: 16 April 2025
Figure 2. Associations of quartiles of serum testosterone levels and FAI with HR achieved at the end of the 4-min step test in premenopausal women in northern Finland birth cohort 1966. Quartile Q1 was used as a reference quartile. Model I is adjusted for time. Model II is adjusted for time, BMI, smoking and
Journal Article
Pernille Mensberg and others
European Journal of Endocrinology, Volume 192, Issue 4, April 2025, Pages 456–465, https://doi.org/10.1093/ejendo/lvaf004
Published: 16 April 2025
Journal Article
Katri Tuorila and others
European Journal of Endocrinology, Volume 192, Issue 5, May 2025, Pages 519–528, https://doi.org/10.1093/ejendo/lvaf080
Published: 16 April 2025
Image
Published: 16 April 2025
Figure 2. Representative western blot of m. Vastus Lateralis before (pre) and after (post) the intervention period. AMPK, AMP-activated protein kinase; CS, citrate synthase; FABPpm, fatty acid binding protein; GLUT4, glucose transporter Type 4; HKII, hexokinase II; IR, insulin receptor expression; LCAD, long